Mary Szela left the role of Director at Averin Capital Acquisition Corp., effective October 16, 2026. As of November 6, 2026, Averin Capital Acquisition Corp. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 29, 2026 to October 16, 2026, naming 1 appointment and 1 departure (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Averin Capital Acquisition Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Averin Capital Acquisition Corp. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-29 to 2026-10-16. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Averin Capital Acquisition Corp. files it.
Also on the record for Averin Capital Acquisition Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 13, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 8.93% of the class | 5%+ stakes | Source |
| March 4, 2026 | Stake report, Schedule 13G, by Sculptor Capital LP | 5.95% of the class | 5%+ stakes | Source |
| March 3, 2026 | Stake report, Schedule 13D/A, by Averin Capital Acquisition Sponsor LLC | 20.44% of the class | 5%+ stakes | Source |
| February 27, 2026 | Stake report, Schedule 13D, by Averin Capital Acquisition Sponsor LLC | 20.44% of the class | 5%+ stakes | Source |
| February 18, 2026 | IPO filing, Form 424B4 | — | IPO filings | Source |
| January 30, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Averin Capital Acquisition Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on Averin Capital Acquisition Corp. and the records around it.
Averin Capital Acquisition Corp. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Sculptor Capital LP also filed stake reports on 40 other companies: Helix Acquisition Corp. III (Oct 2026), Live Oak Acquisition Corp. VI (Oct 2026), Amanat Acquisition Corp (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Watch Averin Capital Acquisition Corp.
Get an email when Averin Capital Acquisition Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Averin Capital Acquisition Corp.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Averin Capital Acquisition Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Averin Capital Acquisition Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Out | Director | 2026-10-16 | 8-K, 2026-10-16 | |
| 2026-05-29 | In | Director | 8-K, 2026-05-29 |
Who leads Averin Capital Acquisition Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Mary Szela, departure reported, effective 2026-10-16 (filed 2026-10-16). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Averin Capital Acquisition Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Averin Capital Acquisition Corp., with the record behind each one.
Find candidates like Director at Averin Capital Acquisition Corp.Every change, in the filing's words
Departing: Mary Szela, Director, effective 2026-10-16
On October 16, 2026, Mary Szela notified the board of directors (the " Board ") of Averin Capital Acquisition Corp. (the " Company ") of her resignation from the Board, as a member of the Board's audit committee (the " Audit Committee ") and as chairperson and a member of the Board's compensation committee (the " Compensation Committee "), effective October 16, 2026.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
- Ms. Szela's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Appointed: Akiko Moni Miyashita, Director
On May 28, 2026, the board of directors (the " Board ") of Averin Capital Acquisition Corp. (the " Company ") appointed Akiko Moni Miyashita as a member of the Board, effective immediately.
- Ms. Miyashita will serve as a member of the first class of directors, which term will expire at the Company's first annual general meeting.
- Akiko Moni Miyashita, age 70, is the Founder of Beacon Hill Strategy Group, a position she has held since October 2024, where she advises chief executive officers and boards of directors on growth strategy, mergers and acquisitions, and AI-enabled transformation.
- She previously served on the board of directors of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2022 to May 2026.
- Ms. Miyashita has over 25 years of experience across strategy, finance and corporate development, with expertise in healthcare and life sciences, technology and global markets.
- Ms. Miyashita previously served as Executive Vice President and Chief Strategy Officer of Valo Health, LLC an AI-native drug discovery and development company, from May 2019 to September 2024, where she led corporate strategy, including business model development, strategic planning, capital allocation and strategic transactions.
- Prior to Valo Health, LLC, Ms. Miyashita served as a Senior Advisor at McKinsey & Company, Inc. from October 2011 to September 2015 and as a Partner at Innosight LLC from August 2015 to August 2019, where she advised chief executive officers and executive teams on strategy, growth and mergers and acquisitions.
Tools for this story
Each opens in a new tab, filled in for Averin Capital Acquisition Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.